SERB Pharmaceuticals completes acquisition of Y-mAbs Therapeutics.

SERB Pharmaceuticals has acquired Y-mAbs Therapeutics, a commercial-stage biopharmaceutical company focused on cancer treatment. The acquisition adds Danyelza to SERB's portfolio and brings deep oncology expertise, expanding its partnerships with the US oncology community and advancing treatments for rare and hard-to-treat cancers. This marks a significant step forward in SERB's growth strategy and vision to help more children and families facing pediatric cancer.

SERB Pharmaceuticals has announced the acquisition of Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on cancer treatment. The acquisition brings Danyelza, a FDA-approved treatment for patients with relapsed or refractory neuroblastoma, into SERB's portfolio. This strategic move not only adds a significant asset to SERB's oncology expertise but also strengthens its partnerships with the US oncology community, advancing treatments for rare and hard-to-treat cancers.

Y-mAbs Therapeutics is known for its innovative Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and the Y-BiClone platform, which generates bispecific antibodies. Danyelza, a humanized monoclonal antibody targeting ganglioside GD2, is a notable addition to SERB's pipeline, offering a potential treatment for pediatric neuroblastoma. This acquisition aligns with SERB's vision to help more children and families facing pediatric cancer.

The acquisition comes at a time when the pediatric clinical trials market is experiencing significant growth. According to DataM Intelligence, the global pediatric clinical trials market size reached US$ 19.74 Billion in 2024 and is expected to reach US$ 31.77 Billion by 2033, growing at a CAGR of 5.5% during the forecast period 2025-2033 Pediatric Clinical Trials Market Size Worth US$ 31.77 Billion by 2033, with a 5.5% CAGR Growth, Report by DataM Intelligence^[2]. The oncology segment dominates this market, with a 32.21% share in 2024, driven by the rising incidence of pediatric cancers and regulatory frameworks that mandate pediatric inclusion in drug development.

North America, with its robust regulatory framework and substantial public and private funding, is expected to dominate the global pediatric clinical trials market with a 42.37% share in 2024. The Asia-Pacific region, on the other hand, is the fastest-growing region due to regulatory modernization and increased healthcare investments, with a CAGR of 6.1% in 2024 Pediatric Clinical Trials Market Size Worth US$ 31.77 Billion by 2033, with a 5.5% CAGR Growth, Report by DataM Intelligence^[2].

This acquisition is a significant step forward in SERB's growth strategy, positioning the company at the forefront of pediatric cancer treatment. As the market for pediatric clinical trials continues to grow, SERB's investment in Y-mAbs Therapeutics and its innovative therapies is likely to yield substantial returns.